We investigated the increased incidence of early-stage breast cancer with micrometastatic lymph node involvement. Breast cancer incidence trends from 1990 through 2002 in the US Surveillance, Epidemiology, and End Results Program catchment area were analyzed. Joinpoint regression was used to show the annual percentage change (APC) in breast cancer incidence trends. The overall incidence of breast cancer among women aged 50 -64 years increased 1.8% (95% confidence interval [CI] = 1.4% to 2.2%) per annum from 1990 through 2002 but decreased in all other age groups. Stage IIA and stage IIB tumor incidence increased (APC for stage IIA from 1996 to 2002 = 61.9%, 95% CI = 51.1% to 73.4%, and APC for stage IIB from 1998 to 2002 = 53.7%, 95% CI = 20.6% to 96.0%). The incidence of micrometastatic lymph node involvement for stage IIA and stage IIB tumors increased during the 1990s, especially after 1997 (APC = 17.3% for both stages), more for estrogen receptor -positive than estrogen receptor -negative disease. Increased use of mammography screening partly explains the increased incidence of early-stage breast cancer. Increases in small tumors with micrometastatic lymph node involvement may be attributable to the increased use of the sentinel lymph node biopsy in community practice.
BRIEF COMMUNICATION
disease using SLNB (48) . We hypothesized that the increase is attributable to the increased use of SLNB in clinical practice. We used joinpoint regression to estimate the annual percentage change (APC) in breast cancer incidence rates, stratifying our analyses at the approximate time that the SLNB was introduced in the United States to assess its impact on the incidence of micrometastatic disease.
Information on women with a fi rst primary breast cancer in 1990 through 2002 was obtained from cancer registries in the US National Cancer Institute ' s Surveillance, Epidemiology, and End Results (SEER) registries (Connecticut, Iowa, New Mexico, Hawaii, Atlanta, Detroit, San Francisco-Oakland, Seattle-Puget Sound, and Utah). Breast cancers were staged using the American Joint Committee on Cancer staging system (AJCC, 3rd edition). Micrometastatic disease was defi ned as metastatic foci of less than 2 mm in diameter in the lymph nodes ( 24 , 25 ) .
Analyses were performed using the SEER-Stat program, version 6.1.4 (available at http://seer.cancer.gov/seerstat/ ). Incidence rates per 100 000 were age adjusted to the 2000 US standard ( http:// seer.cancer.gov/stdpopulations/single_age. html ). Breast cancer incidence trends were analyzed by joinpoint regression analysis, which estimates the APC in rates by selecting the best fi tting regression line segment.
Joinpoint selects time periods within an
Population-based mammographic screening has contributed to the increased detection of small (<2 cm), early-stage tumors ( 1 -4 ) . In addition, in the United States, increased incidence of tumors larger than 2 cm has been noted and attributed to changes in reproductive patterns and increased use of population-based mammography ( 4 ) . Although mammography is likely to have contributed to the increased incidence of small, localized tumors, it may not be solely responsible for the increased incidence of regional disease, which can include larger tumors with lymph node metastases and tumor extension beyond the primary site. The increase in regional disease may therefore be also due to the introduction of the sentinel lymph node biopsy (SLNB) ( 5 -7 ) .
The sentinel node is the primary drainage destination of any metastasizing tumor cells ( 8 , 9 ) and can be identifi ed using either a blue dye, a radiolabeled colloid, or a combination of the two ( 10 , 11 ) . Research indicates that there can be more than one sentinel node per tumor ( 47 ) . SLNB involves meticulous pathological examina-tion, which can lead to upstaging of disease ( 12 ) . Although it is considered to be a potentially important experimental tool for identifying occult lymph node metastases ( 13 , 14 ) , SLNB is not recommended for routine clinical use ( 15 -17 ) . Evidence suggests, however, that SLNB has been incorporated into national practice ( 18 -21 ) . Its effectiveness at distinguishing micro-from macrometastatic disease remains controversial, and its false-negative rate of 0% -15% necessitates additional axillary lymph node dissection (ALND) ( 6 , 15 , 22 , 23 ) .
Our US population -based study focused on the increased incidence of stage IIA and stage IIB disease with micrometastatic lymph node involvement. Stage IIA disease is defi ned as no tumor or tumor less than 2 cm with one to three positive lymph nodes, or tumor 2-5 cm in diameter without evidence of disease in axillary lymph nodes. Stage IIB disease is defi ned as tumor 2-5 cm in diameter with one to three positive lymph nodes, or tumor larger than 5 cm without any disease in the chest wall or lymph nodes. For both stage IIA and IIB, disease can be identifi ed as microscopic overall time frame so that the incidence trend is as uniform as possible within each selected time period ( 26 ) . Three joinpoints, each denoting a statistically signifi cant change in trend, were allowed for each model. Incidence trends were based on observed data and are not adjusted for reporting delay ( 27 ) .
During the 1980s, stage II node-positive breast cancer incidence declined due to the detection of small tumors using populationbased mammography ( 49 , 50 ) . By contrast, in the 1990s when that of stage II tumors with one examined lymph node increased ( Table 1 ) ( 4 ). Stage II tumors are, by defi nition, small tumors (<5 cm) with evidence of disease in a maximum of three lymph nodes, or larger tumors of more than 5 cm without lymph node involvement. As Table 1 shows, our fi ndings indicate that stage IIA tumors that were smaller than 2 cm with one examined lymph node increased 7.2% per annum (95% confi dence interval [CI] = 0.1 to 14.9) from 1990 to 1996 and 61.9% per annum (95% CI = 51.1 to 73.4) from 1996 to 2002 ( Table 1 ). Stage IIB tumors (2 -5 cm with one examined lymph node) increased 10.6% per annum (95% CI = 1.7 to 20.2) from 1990 to 1998 and 53.7% per annum (95% CI = 20.6 to 96.0) from 1998 to 2002. These fi ndings are similar to those of a Dutch population -based study, which documented increased incidence of tumors sized more than 2 cm at the advent of mammography followed by a decrease and subsequent increased incidence of nodepositive tumors after the prevalent screening round, which they attributed to the introduction of SLNB ( 7 ) . Our fi nding of an increase in stage II node-positive cancers may refl ect a change in the clinical management of breast cancer, specifi cally the increased use of SLNB.
Sentinel lymph node biopsy use in academic centers is estimated to have increased from 8% in 1997 to 58% in 2000 ( 28 ) , and in the SEER registries, an increased prevalence of SLNB from 1998 through 2000 of 20% -30% has been documented ( 21 ) . This trend is likely to have continued in recent years. To assess the impact of the increased use of SLNB on breast cancer incidence, we stratifi ed our analysis of the incidence of early-stage tumors categorized by size and lymph node involvement in December 1996, which is approximately the time when SLNB was introduced in the United States ( 28 ) . We observed ( 34.8) . Although we could not determine the exact use of SLNB, our fi ndings suggest the increased dissemination of the procedure in community clinical practice.
Our fi ndings indicate an increased incidence of breast cancer with micrometastatic lymph node involvement before the introduction of SLNB (from 1990 to 1996) in routine clinical practice in the United States (about 1997) ( 28 ) . This may be attributable to the increasing use of population-based mammography and a general increase in breast cancer awareness. However, the increase in micrometastatic lymph node disease in the pre-SNLB era may also refl ect a gradual introduction of the technique into surgical practice. Mastery of the surgical procedure has an associated learning curve ( 29 ) , and surgeons need to perform 20 -30 SLNB procedures in conjunction with ALND to achieve a high rate of accuracy ( 30 , 31 ) . Such a learning phase where SLNB is performed in conjunction with ALND has been followed by a mature phase where ALND is performed only if a positive SLNB was identifi ed in patients ( 28 ) . The increased incidence of micrometastatic lymph node disease during the 1990s may therefore be due to the combined effect of this learning curve and increased use in routine surgical practice ( 17 ) .
SLNB is less invasive than ALND ( 32 -34 ) and facilitates more accurate staging ( 6 , 28 , 35 , 36 ) . Research has indicated that 25% of patients with sentinel node micrometastases had residual axillary disease ( 21 ), whereas patients with a single sentinel node micrometastasis and more than four disease-free sentinel nodes were unlikely to have axillary disease ( 37 ) . It is estimated that 60% -80% of patients with small breast tumors have tumor-free sentinel nodes ( 35 ) . Because ALND is associated with long-term morbidity, including lymphedema, arm pain, and upper arm paresthesia, SLNB is a more accurate and less in vasive staging procedure.
SLNB, used in preference to ALND, may be the cause of a stage migratory or "Will Rogers" effect ( 12 , 36 , 38 ) . For exam-ple, if SLNB reveals micrometastatic lymph node foci, stage IIA disease (T2N0 -tumors sized 2 -5 cm with no disease in the lymph nodes [N0]) could become stage IIB (T2N1tumors sized 2 -5 cm with one positive, micrometastatic lymph node). Thus, before the advent of SLNB, stage II node-positive breast cancers may have been considered to be stage I, node-negative disease. Our fi ndings may refl ect the impact of such upstaging on breast cancer incidence rates.
A number of distinct techniques are used to identify micrometastatic tumor cells including hematoxylin and eosin (H & E) staining, immunohistochemistry (IHC), and reverse transcription-polymerase chain reaction (RT-PCR). Schouten et al. ( 7 ) reported that, during the introduction of the SLNB technique, IHC and SLNB were used in the Netherlands to improve the
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Prior knowledge
The effect of the recent increase in the use of sentinel lymph node biopsy on the incidence of breast cancer with micrometastatic lymph node involvement was unknown.
Study design
Regression analysis was used to identify trends in the incidence of breast cancer according to stage and lymph node involvement based on data from the Surveillance, Epidemiology, and End Results Program.
Contribution
Increases in the incidence of breast cancer with micrometastatic lymph node involvement were identified that were consistent with an effect of increased detection due to more widespread use of sentinel lymph node biopsy in recent years.
Implications
The results of this study predict that as the use of sentinel lymph node biopsy continues to increase, the incidence of breast cancer with lymph node metastases will increase in parallel.
Limitations
The study was conducted without the knowledge as to which patients underwent sentinel lymph node biopsy and without the information on trends in the use of the procedure that would be needed for a more conclusive assessment of the effects of sentinel lymph node biopsy on breast cancer diagnosis.
Downloaded from https://academic.oup.com/jnci/article-abstract/99/13/1044/941411 by guest on 06 December 2018 accuracy of detecting lymph node metastases ( 7 ) . A study by de Widt-Levert detected micrometastatic disease by IHC only, however, some IHC-positive cells in sentinel nodes can be benign epithelial cells ( 12 ) . The SEER database, used in this study, includes micrometastatic disease identifi ed by H & E staining, and not that identifi ed by IHC or RT-PCR (April Fritz: unpublished data). H & E staining is said to better predict micrometastases than IHC ( 39 , 40 ) .
To avoid false-positive results using IHC, the AJCC 5 th edition indicates that node-negative disease can incorporate "isolated tumor cells" in the lymph nodes (i.e., histologically positive IHC and <0.2 mm) ( 25 ) . These cells usually lack proliferative ac tivity ( http://www.cancerstaging.org ). Futhermore, the AJCC 6 th edition considers an IHC-positive and/or an RT-PCRpositive sample as N 0 i+ (isolated tumor cells by H & E or IHC, <0.2 mm) and N 0 (mol+) (no regional lymph node, but positive by RT -PCR) rather than N 1 (1 -3 positive lymph nodes or evidence of micrometastatic disease by SLNB) ( 17 ) . Thus, while parallel use of IHC with H & E has increased the accuracy of staging slightly, its use is unlikely to have contributed to a stage-migratory effect ( 41 ) or to the increased incidence of stage IIA and stage IIB cancers, observed in this study. Along with tumor size and type, patient age is an independent risk factor for axillary metastases in breast cancer ( 36 ) . Like the study by Schouten et al. ( 7 ) , we found increased breast cancer incidence during the 1990s in the United States, particularly among women aged 50 -64 years (APC = 1.8%, 95% CI = 1.4 to 2.2) (data not shown). These peri-/postmenopausal women were also those invited to participate in population-based screening during the late 1980s and 1990s ( 38 ) . Many of these women may also have used hormone replacement therapy (HRT) because 70% -80% of American gynecologists prescribed HRT for at least 10 years to women with an intact uterus after 1970 ( 42 , 43 ) . HRT increases the risk of early-stage, low-grade, estrogen receptor -positive (ER+) breast cancers ( 37 , 43 ) . Consistent with this, we observed substantially increased incidence of ER+ tumors. From 1990 -2002, the incidence of stage IIB ER+ disease with micrometastatic lymph node involvement in creased by 13.4% per annum (95% CI = 10.3 to 16.5) ( Table 3 ). There were also increases of a slightly lower magnitude in the incidence of estrogen receptor -negative (ER − ) tumors. For example, stage IIB ER − disease with micrometastatic lymph node involvement increased by 12.1% (95% CI = 5.5 to 19.1) ( Table 3 ). It has been noted that women prescribed HRT often belong to higher social classes with better healthcare and screening access, thus increasing the likelihood of cancer detection at an earlier stage ( 44 ) . Our fi ndings, indicating consistent increases in micrometastatic disease for each stage and ER status, suggest that although HRT use may have contributed to the increased incidence of the ER+ breast tumors, HRT use cannot solely be responsible for this increased incidence because the incidence of ER − tumors with micrometastatic lymph node involvement also increased. This population-based study tracked breast cancer incidence trends for a 12-year period (1990 -2002) , focusing primarily on early-stage disease. Limitations to our study include a) no adjustment for any sociodemographic factors (e.g., socioeconomic status, use of HRT, etc.) or for other clinical factors e.g., comorbidity, which may have impacted on a woman's tendency to attend screening and thereby facilitate diagnosis of their cancer at an earlier stage and b) before 1998, SEER did not identify the type of lymph node surgery -thus, it was not possible to estimate directly the extent of lymph node surgery in our patient population. We therefore could not determine the specifi c impact of SLNB on the incidence of breast tumors with micrometastatic lymph node involvement. Since then, however, the scope of lymph node surgery has been recorded for use in future studies.
Patients diagnosed with sentinel (pathologically confi rmed) node-negative disease are believed to have a better prognosis than those with clinically confi rmed nodenegative disease ( 28 , 45 , 46 ) . We have highlighted the increased incidence of early-stage breast cancer with lymph node involvement, specifi cally, cancer with micrometastatic lymph node involvement. While the use of SLNB in community practice continues to increase, it is expected that cases with lymph node metastases also will continue to increase. 
